PTO/SB/08A (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Reperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO RMATION DISCLOSURE TEMENT BY APPLICANT

Complete if Known			
Application Number	10/579,125		
Filing Date	31 July 2007		
First Named Inventor	David James		
Group Art Unit	1641		
Examiner Name	Not yet assigned		
Attorney Docket Number	42-000500US		
Date Submitted	September 24, 2007		

(use as many sheets as necessary)

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent Docur Number	ment Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal

	FOREIGN PATENT DOCUMENTS							
			Foreign Patent Docume			Date of Publication	Pages, Columns, Lines,	
Examiner Initials	Cite No.	Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T
	1	wo	2004/055181	A1	Garvan Institute of Medical Research	07-01-2004		

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
	2	ABU-ELHEIGA ET AL. (2003) "Acetyl-CoA carboxylase 2 mutant mice are protected against obesity and diabetes induced by high-fat/high-carbohydrate diets," <i>PNAS</i> , 100(18):10207-10212.	
	3	CHIUSAROLI ET AL. (2003) "Deletion of the gene encoding c-Cbl alters the ability of osteoclasts to migrate, delaying resorption and ossification of cartilage during the development of long bones," <i>Developmental Biology</i> , 261:537-547.	
	4	FARESE (2002) "Function and dysfunction of aPKC isoforms for glucose transport in insulinsensitive and insulin-resistant states," <i>Am. J. Physiol. Endocrinol. Metab.</i> , 283(1):E1-11.	
	5	MOLERO ET AL. (2004) "c-Cbl-deficient mice have reduced adiposity, higher energy expenditure, and improved peripheral insulin action," <i>J. Clinical Investigation</i> , 114(9):1326-1333.	
•	6	GRIFFITHS ET AL. (2003) "Cbl-3-deficient mice exhibit normal epithelial development," Molecular and Cellular Biology, 23(21):7708-7718.	
	7	JOAZEIRO ET AL. (1999) "The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase," <i>Science</i> , 286(8):309-312.	
	8	KHAN AND PESSIN (2002) "Insulin regulation of glucose uptake: a complex interplay of intracellular signaling pathways," <i>Diabetologia</i> , 45:1475-1483.	
	9	LIU ET AL. (2003) "The roles of Cbl-b and c-Cbl in insulin-stimulated glucose transport," <i>J. Biological Chemistry</i> , 278(38):36754-36762.	
	10	MELIKOVA ET AL. (2003) "Cbla polyfunctional regulator of cellular processes," <i>Tsitologiia</i> , 45(11):1134-1148. Abstract only available. <i>PubMed.</i>	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08A (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE action of information unless it contains a valid OMB control number.

Order the Paperwork Reduction Act of 1995, no persons are n	equired to respond to a collection of informa-	ation unless it contains a valid ONB control number.		
Substitute for form 1449A-B/PTO	C	Complete if Known		
	Application Number	10/579,125		
INFORMATION DISCLOSURE	Filing Date	31 July 2007		
STATEMENT BY APPLICANT	First Named Inventor	David James		
	Group Art Unit	1641		
	Examiner Name	Not yet assigned		
(use as many sheets as necessary)	Attorney Docket Number	42-000500US		
	Date Submitted	September 24, 2007		

11	MURPHY ET AL. (1998) "Tissue hyperplasia and enhanced T-cell signaling via ZAP-70 in c-Cbl deficient mice," <i>Molecular and Cellular Biology</i> , 18(8):4872-4882.	
12	MUSI ET AL. (2002) "Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes," <i>Diabetes</i> , 51(7):2074-2081.	
13	SOHN ET AL. (2003) "Cbl-b negatively regulates B cell antigen receptor signaling in mature B cells through ubiquitination of the tyrosine kinase Syk," <i>J. Experimental Medicine</i> , 197(11):1511-1524.	
14	VOLLENWEIDER (2003) "Insulin resistant states and insulin signaling," Clin. Chem. Lab. Med., 41(9):1107-1119.	
15	WINDER ET AL. (2000) "Activation of AMP-activated protein kinase increases mitochondrial enzymes in skeletal muscle," <i>J. Appl. Physiol.</i> , 88:2219-2226.	

Examiner		Date	
Signature	·	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.